Related Experiment Video
Updated: Dec 22, 2025
11:00
Real-Time Quantitative Measurement of Tumor Cell Migration and Invasion Following Synthetic mRNA Transfection
Published on: June 23, 2023
2.0K
CRISP3 expression drives prostate cancer invasion and progression
Marianna Volpert1, Luc Furic1,2,3,4, Jinghua Hu1,5
1Department of Anatomy and Developmental Biology, Monash University, Clayton, Victoria, Australia.
Endocrine-Related Cancer
|May 2, 2020
Summary
Cysteine-rich secretory protein 3 (CRISP3) drives prostate cancer progression by enhancing cell migration and invasion. Targeting CRISP3 offers a potential therapeutic strategy for prostate cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Prostate cancer progression involves increased cell migration and invasion.
- Cysteine-rich secretory protein 3 (CRISP3) is significantly upregulated in prostate cancer.
Purpose of the Study:
- To investigate the role of CRISP3 in prostate cancer progression.
- To identify CRISP3 as a potential therapeutic target.
Main Methods:
- Utilized a genetically engineered mouse model of prostate cancer.
- Employed human and mouse prostate cancer cell lines.
- Performed mass spectrometry to analyze protein abundance changes.
Main Results:
- CRISP3 production accelerated prostate cancer progression in vivo.
- Exposure to CRISP3 enhanced prostate cancer cell motility and invasion.
- CRISP3 altered the abundance of cell-cell adhesion proteins, including LASP1 and TJP1.
Conclusions:
- CRISP3 acts as a pro-tumorigenic factor in prostate cancer.
- CRISP3 is a validated therapeutic target for prostate cancer intervention.
Related Concept Videos
01:35Cancer Cell Migration through Invadopodia
3.1K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
3.1K
03:03mTOR Signaling and Cancer Progression
4.5K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.5K
02:07Tumor Progression
7.1K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.1K
02:23Abnormal Proliferation
5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K